CLS announces first glioblastoma patient treated with the MR-guided Laser Interstitial Thermal Therapy (MRg LITT) in the study at Skåne University Hospital
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS), which develops advanced innovative products for high-precision image guided laser ablation, today announced that the first patient has been safely treated in the clinical trial at Skåne University Hospital (SUS) aiming to evaluate MR-guided Laser Interstitial Thermal Therapy (MRg LITT) for glioblastoma ablation.
The CLS sponsored study at Skåne University Hospital is a single-center, single-arm, prospective clinical trial, with the aim to evaluate safety and feasibility of using minimally invasive MRgLITT in brain, for ablation of tumor tissue in patients diagnosed with glioblastoma.
The team at Skåne University Hospital utilizes CLS’s latest thermal therapy product branded ClearPoint PrismTM Neuro Laser Therapy System, in combination with ClearPoint® Neuro Navigation System, to perform the MRg LITT procedure.
“The clinical trial with minimally invasive laser thermal treatment of patients with recurrent malignant brain tumors, glioblastoma, has now started at Skåne University Hospital and the treatment of the first patient could be carried out as planned. The treatment was performed, for the first time in Sweden, in a magnetic resonance imaging suite to avoid transporting the patient between surgery and the MRI-suite” stated Dr. Peter Siesjö, Neurosurgeon and principal investigator of the study at Skåne University Hospital.
“CLS is excited that this significant milestone has been reached in our clinical study investigating the use of our product in MRg- LITT for ablation of glioblastoma, a study that is conducted in collaboration with the department of neurosurgery at Skåne University Hospital here in Lund in Sweden. The aim of the study is to provide initial data for CLS planned CE marking of the product in Europe.” stated Dan J. Mogren, CEO of Clinical Laserthermia Systems AB.
In September of this year CLS received US-FDA marketing clearance for the ClearPoint PrismTM Neuro Laser Therapy System, for use in neurosurgery, in USA. The product is commercialized through CLS´ global distributor ClearPoint Neuro Inc..
The information was submitted for publication, through the agency of the contact person set out below, on December 12, 2022, at 08:30 CET.
Contact Information:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 – (0)705 – 90 11 40 E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se